Chemistry:F-14413
From HandWiki
F-14413, also known as 5-fluoro-methoxyidazoxan, is an α2-adrenergic receptor antagonist or inverse agonist which was under development for the treatment of Alzheimer's disease and Parkinson's disease in France but was never marketed.[1][2][3][4] It is a derivative of idazoxan.[3][4] The drug's route of administration was unspecified.[1] It is said to be potent and highly selective as an α2-adrenergic receptor modulator.[5][4] F-14413 was under development by Pierre Fabre.[1][2][5] It reached the preclinical research stage of development prior to its discontinuation.[1][2] F-14413 was first described in the scientific literature by 2001,[5] while its latest developmental update was in 2003.[1]
See also
- List of investigational Parkinson's disease drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "F 14413". 16 November 2009. https://adisinsight.springer.com/drugs/800019997.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on F-14413 with Synapse". 25 April 2026. https://synapse.patsnap.com/drug/d91cde73dc2746f6bbcc3529665cca3f.
- ↑ 3.0 3.1 "Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb". Experimental Neurology 194 (2): 444–456. August 2005. doi:10.1016/j.expneurol.2005.03.004. PMID 16022870.
- ↑ 4.0 4.1 4.2 "Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist". Antioxidants & Redox Signaling 8 (5–6): 873–883. 2006. doi:10.1089/ars.2006.8.873. PMID 16771677.
- ↑ 5.0 5.1 5.2 "Absolute configuration of (+)-(S)-2-(5-fluoro-2-methoxy-1,4-benzodioxan-2-yl)imidazolinium bromide". Acta Crystallographica. Section C, Crystal Structure Communications 57 (Pt 4): 483–484. April 2001. doi:10.1107/s0108270101000981. PMID 11313601. Bibcode: 2001AcCrC..57..483B.
 |  |
